课题基金 / 基金详情

Clinical Development of 4-Hydroperoxyifosfamide

Clinical Development of 4-Hydroperoxyifosfamide
4-氢过氧异环磷酰胺的临床开发
批准号:
7109630
负责人:
Lee ROY MORGAN
金额:
$29.43万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-01-01 至 2008-04-30

项目摘要

项目成果

Lee ROY MORGAN的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):4-氢过氧异环磷酰胺(HOO-IFOS)是异环磷酰胺(IFOS)的初始代谢产物4-HO-IFOS的稳定,预活化形式(过氧化物)。在生理条件下,HOO-IFOS会自发开环并转化为IFOS的活性细胞毒性代谢物异磷酰胺芥子气(IPM)。本研究的目的是合成足够数量的4-氢过氧异环磷酰胺(HOO-IFOS),以记录和验证其纯度和稳定性。冻干产品将在爱荷华大学制药服务部根据GLP/GMP指南制备,用于晚期癌症患者的临床使用。将验证GC/MS和HPLC测定法用于散装和药用级药物的定量。将在GLP设施使用最终产品对小鼠和犬进行为期3天的给药方案毒理学研究。在接受HOO-IFOS治疗的犬中,监测血浆HOO-IFOS PK和丙烯醛/氯乙醛水平的试验将最终确定。在上述所有内容完成并提交给FDA后,将准备IND包。总之,HOO-IFOS对人胶质母细胞瘤和乳腺癌异种移植物以及cpa耐药白血病小鼠模型具有更好的抗癌活性。SBIR申请的目标将是开发一种新的前药,4-氢过氧异环磷酰胺(HOO-IFOS),它将在体内产生异磷酰胺芥子气(IPM),减少相关毒性-氯乙醛和丙烯醛-副产物的形成,通常在IFOS期间产生。
英文摘要
DESCRIPTION (provided by applicant): 4-Hydroperoxyifosfamide (HOO-IFOS) is a stable, pre-activated form (peroxide) of 4-HO-IFOS, the initial metabolite of Ifosfamide (IFOS). Under physiological conditions HOO-IFOS under goes spontaneously ring opening and conversion to isophosphoramide mustard (IPM), the active cytotoxic metabolite of IFOS. The objective of the proposed research is to synthesize 4-hydroperoxyifosfamide (HOO-IFOS) in sufficient quantity to document and validate purity and stability. A lyophilized product will be prepared at The University of Iowa, Pharmaceutical Services under GLP/GMP guidelines for clinical use in patients with advanced cancer. GC/MS and HPLC assays will be validated for quantification of bulk and pharmaceutical grade drug. Toxicology studies using a 3-day dosing regime in mice and dogs will be conducted at a GLP facility using the final product. An assay to monitor plasma HOO-IFOS PK and acrolein/chloroacetaldehyde levels in dogs receiving HOO- IFOS will be finalized. An IND package will be prepared after all the above has been finalized and submitted to the FDA. In summary - HOO-IFOS had improved anticancer activities vs. human glioblastoma and breast cancer xenografts and CPA-resistant leukemia murine models. The goal of the SBIR application will be to develop a new pro-drug, 4-hydroperoxyifosfamide (HOO-IFOS) that will generate in vivo - isophosphoramide mustard (IPM) - with reduced formation of associated toxic - chloroacetaldehyde and acrolein - by-products, normally produced during IFOS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Phase I Clinical Trial: Binary Therapy with DM-CHOC-PEN and WBRT in Adults with Cancer Involving the CNS
  • 批准号:
    9253561
  • 项目类别:
  • 资助金额:
    $14.33万
  • 财政年份:
    2017
  • 负责人:
    Lee ROY MORGAN
  • 依托单位:
Phase I Clinical trial with 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Children with Cancer Involving the CNS
  • 批准号:
    9047161
  • 项目类别:
  • 资助金额:
    $9.04万
  • 财政年份:
    2016
  • 负责人:
    Lee ROY MORGAN
  • 依托单位:
Phase I Clinical trial with 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Children with Cancer Involving the CNS
  • 批准号:
    9201324
  • 项目类别:
  • 资助金额:
    $9.04万
  • 财政年份:
    2016
  • 负责人:
    Lee ROY MORGAN
  • 依托单位:
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN: A Phase II Clinical Trial in Adolescents/Young Adults (AYA)with CNS Malignancies
  • 批准号:
    9791343
  • 项目类别:
  • 资助金额:
    $51.95万
  • 财政年份:
    2016
  • 负责人:
    Lee ROY MORGAN
  • 依托单位:
海外基金